Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »
Sep 1, 2009 (Vol. 29, No. 15)

Q&A on Sartorius Stedim Biotech/SAFC Deal

Looking at the Rationale for the Agreement and What the Two Companies Plan to Offer

  • Click Image To Enlarge +
    Maik Jornitz

    SAFC Biosciences and Sartorius Stedim Biotech recently signed a global partnership agreement that combines Sartorius Stedim Biotech’s expertise in filtration and liquid-handling systems with SAFC Biosciences’ proficiency in development and manufacturing of cell culture media and downstream purification products.

    The companies will combine their expertise in generating application data on filter and mixing performance with critical purification buffers and cell culture media. Similarly, extractable and leachable data will be generated with buffers and media, and with filters and biobag combinations.

    In addition, SAFC expects to utilize Sartorius Stedim Biotech’s technology for storage and mixing of cell culture media to optimize its fluid/powder handling system.

    To obtain a further perspective on the agreement, GEN interviewed Maik Jornitz, group vp, product management, filtration/ fermentation technologies at Sartorius Stedim Biotech, and Bruce Lehr, director of marketing at SAFC Biosciences.

  • Click Image To Enlarge +
    Bruce Lehr


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »